Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
Dinh P, Graham JD, Elder EN, Kabir M, Doan TB, French J, Meybodi F, Hui R, Wilcken NR, Harnett PR, Hsu J, Stuart KE, Wang T, Ahern V, Brennan M, Fox SB, Dear RF, Lim E, White M, Mann GB, Pathmanathan N.
Dinh P, et al. Among authors: dear rf.
Breast Cancer Res Treat. 2022 Feb;191(3):501-511. doi: 10.1007/s10549-021-06456-5. Epub 2021 Dec 1.
Breast Cancer Res Treat. 2022.
PMID: 34853987